Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 23, 2025 11:00 ET | Source: Innovate GBM

Innovate GBM’s 2025 Investment Playbook Year to Date Review: Building a New Market for Brain Cancer Investments and Breakthroughs

Innovate GBM’s 2025 Impact Report highlights $170M in funding commitments, uniting the Community to grow an Ecosystem of innovation and progress.
September 23, 2025 07:00 ET | Source: BPGbio

BPGbio Welcomes Back NAi Interrogative Biology® Platform Co-Inventor Slava Akmaev, Ph.D., as Chief Operating Officer and Chief AI Officer

Seasoned AI-Biotech veteran strengthens the company’s leadership in AI and mitochondrial medicine Co-Inventor of AI platform boosts company’s momentum in advancing late-stage assets to...
September 04, 2025 07:00 ET | Source: BPGbio

BPGbio Announces Completion of Enrollment for Phase 2b Trial of BPM31510 for Glioblastoma (GBM)

BPGbio Announces Completion of Enrollment for Phase 2b Trial of BPM31510 for Glioblastoma (GBM) and Topline Phase 2b clinical data expected in 1H 2026
June 24, 2025 09:03 ET | Source: Innovate GBM

Innovate GBM Rings the NASDAQ Closing Bell in Honor of Brain Tumor Patients and Community

Innovate GBM rings the NASDAQ closing bell to honor glioblastoma patients and to spotlight the urgent need for brain tumor investment and innovation.
May 05, 2025 10:00 ET | Source: Brain Cancer Canada

MicroRNAs Research Initiative in Glioblastoma Stem Cells Awarded $85K by Brain Cancer Canada

TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is pleased to announce a $85,000 grant for a cutting-edge research initiative led by Dr. Leonardo Salmena at the University of Toronto....
March 19, 2025 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
March 07, 2025 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda
January 09, 2025 06:00 ET | Source: GENENTA SCIENCE SPA

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing
November 25, 2024 07:00 ET | Source: IN8bio, Inc

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
October 04, 2024 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

October 4, 2024 Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma Cohort A Data on Overall Survival Compare Favorably with...